Meitheal Logo (Mh Logo)
Yusimry Injection, Solution
Product Images NDC 71288-816
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Yusimry (NDC 71288-816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Fig 01)
A line graph depicting the percentage of ACR 20 responders over time in weeks. It compares patients receiving 40 mg of YUSIMRY (adalimumab-aqvh) every other week to those on placebo. The graph shows a higher percentage of responders in the treatment group compared to placebo throughout the study duration of up to 48 weeks.*
Figure 2 (Fig 02)
A line graph depicting the percentage of ASAS 20 Response over time (weeks) comparing Adalimumab and placebo groups. The x-axis shows time in weeks from 0 to 26, and the y-axis shows the percentage response from 0 to 70%. Adalimumab shows a higher response rate starting early and maintaining above 50%, while placebo response peaks below 30% and declines over time.*
Figure 3a (Fig 03a)
A line graph showing treatment failure rate (%) over time (months) comparing placebo and adalimumab groups. The graph depicts a higher failure rate for placebo over the study period, with time on the x-axis and treatment failure rate on the y-axis. Data points and patient numbers are shown below the x-axis.*
Figure 3b (Fig 03b)
A line graph depicting treatment failure rate (%) over time (months) comparing three groups: Treatment, Placebo, and Adalimumab. The x-axis shows time from 0 to 20 months, and the y-axis shows treatment failure rate from 0 to 100%. Three curves illustrate different failure rates for each group across the study duration.*
Carton Label (Two 40 mg/0.8 mL Single-Dose Prefilled Syringes)
YUSIMRY (adalimumab-aqvh) Injection 40 mg/0.8 mL single-dose prefilled syringes. The carton contains 2 single-dose prefilled syringes, medication guide, prescribing information, and instructions for use. Labeled for subcutaneous use only, with storage instructions to keep refrigerated and notes on temporary room temperature storage. Labeler is Meitheal Pharmaceuticals Inc.*
Carton Label (Two 40 mg/0.8 mL Single-Dose Pens)
YUSIMRY (adalimumab-aqvh) 40 mg/0.8 mL injection in a single-dose prefilled pen format. The carton contains 2 single-dose prefilled pens, a medication guide, prescribing information, and instructions for use. It is labeled for subcutaneous use only and is registered by Meitheal Pharmaceuticals Inc. The label indicates refrigeration storage requirements and dosage guidance.*
Figure 1 Prefilled Pen Ifu (Fig Ifu 01 Ai)
An instructional illustration showing a hand placing a medication box into a refrigerator, with an arrow indicating the action. A clock icon shows a time interval of 15-30 minutes, suggesting the medication should be refrigerated for this duration before use.*
Yusimry Prefilled Syringe (Fig Ifu 01)
An instructional illustration showing parts of a prefilled syringe for injection, labeled with the plunger, finger grip, and needle cover. The injector is designed for subcutaneous administration.*
Figure 2 Prefilled Pen Ifu (Fig Ifu 02 Ai)
Illustration showing step 2 in the use of an injection device, focusing on a window indicator on the side of a prefilled syringe or pen injector. The zoomed-in view highlights a partially filled indicator inside the window, likely indicating medication presence or injection progress.*
Figure 1 Prefilled Syringe Ifu (Fig Ifu 02)
An instructional illustration showing a hand placing a rectangular box into a refrigerator, indicating proper storage of the medication.*
Figure 3 Prefilled Pen Ifu (Fig Ifu 03 Ai)
Illustration showing a used injection pen, a trash container, a cotton ball, and a small antiseptic pad. Below is a circular inset depicting hands being washed under a running tap water.*
Figure 2 Prefilled Syringe Ifu (Fig Ifu 03 V2)
An instructional illustration depicting proper disposal steps for a needle and syringe. It shows a packaged syringe, a designated sharps disposal container, handwashing under a faucet, a crumpled tissue, and a small wrapped item, emphasizing hygiene and safety after injection.*
Figure 4 Prefilled Pen Ifu (Fig Ifu 04 Ai)
An instructional illustration showing recommended injection sites for YUSIMRY (adalimumab-aqvh) injection solution. The diagram highlights the abdomen and thighs as suitable areas for subcutaneous injections, with a close-up insert depicting a hand applying a patch or injection site preparation.*
Figure 3 Prefilled Syringe Ifu (Fig Ifu 04 V2)
An instructional diagram showing recommended injection sites for YUSIMRY (adalimumab-aqvh) 40 mg/0.8 mL subcutaneous injection. The image identifies three areas on the body labeled as 'Injectable Areas': the abdomen (excluding a 2-inch area around the navel) and the front of the thighs. An inset shows a hand holding the injection device against the skin.*
Figure 5 Prefilled Pen Ifu (Fig Ifu 05 Ai)
Instructional diagram showing a two-hand action to remove the cap from a prefilled pen injector by pulling the cap away from the pen, indicated by directional arrows.*
Figure 4 Prefilled Syringe Ifu (Fig Ifu 05)
An instructional illustration showing hands detaching or preparing parts of a subcutaneous injection device. Arrows indicate pulling or separating two components, likely a cap or needle cover from the injection pen or syringe for the YUSIMRY adalimumab-aqvh 40 mg/.8mL solution for injection.*
Figure 6 Prefilled Pen Ifu (Fig Ifu 06 Ai)
An instructional illustration showing a hand holding a YUSIMRY prefilled syringe vertically at a 90-degree angle over a flat surface, indicating the proper syringe position for administration.*
Figure 5 Prefilled Syringe Ifu (Fig Ifu 06)
An instructional illustration showing a hand holding a syringe poised for subcutaneous injection. A close-up inset highlights the site of injection on the skin, indicating proper technique for administering an injection under the skin.*
Figure 7 Prefilled Pen Ifu (Fig Ifu 07 Ai)
An instructional illustration showing a hand holding an injection pen vertically with a downward arrow labeled "First 'Click'" indicating activation or preparation of the YUSIMRY injection device for subcutaneous use.*
Figure 6 Prefilled Syringe Ifu (Fig Ifu 07)
An instructional illustration showing the correct technique for subcutaneous injection of YUSIMRY (adalimumab-aqvh). It depicts a syringe being injected at a 45-degree angle into either the abdomen or thigh, demonstrating hand placement and injection angle for proper administration.*
Figure 8 Prefilled Pen Ifu (Fig Ifu 08 Ai)
An instructional illustration showing a hand holding an injection device labeled with orange and gray parts. The image instructs to count to five after hearing the second 'Click' while the device is held vertically with its tip down, indicating proper injection or preparation technique.*
Figure 7 Prefilled Syringe Ifu (Fig Ifu 08)
An instructional illustration depicting a person administering a subcutaneous injection using a syringe into the abdomen. The hand is shown holding the syringe at the injection site, indicating the direction of injection for the drug YUSIMRY (adalimumab-aqvh) 40 mg/0.8 mL solution for injection.*
Figure 9 Prefilled Pen Ifu (Fig Ifu 09 Ai)
An instructional diagram showing a hand holding a syringe vertically with the thumb pressing on the bottom, and an upward arrow indicating the syringe should be pushed or moved upwards. This image is part of usage instructions for a subcutaneous injection product.*
Figure 8 Prefilled Syringe Ifu (Fig Ifu 09)
An instructional illustration showing a hand disposing of a used syringe or needle into a sharps container labeled "SHARPS." The image emphasizes the safe disposal of injectable medical waste, likely related to the administration of an injectable drug like YUSIMRY (adalimumab-aqvh) 40 mg/0.8 mL subcutaneous injection.*
Figure 10 Prefilled Pen Ifu (Fig Ifu 10 Ai)
An illustration showing a hand disposing of a syringe into a sharps container. The syringe appears to be partially filled and the image suggests safe disposal of injection equipment.*
Calendar (Fig Ifu 10)
Yusimry Prefilled Pen (Fig Ifu P01 Ai)
An instructional diagram showing parts of the YUSIMRY 40 mg/0.8 mL prefilled pen injection device before use, including the clear cap, needle, gray needle guard, viewing window, gray plunger, prefilled pen body, and label with expiration date. It also shows the orange indicator visible after use.*
Calendar (Fig Ifu P02 Ai)
Illustration of a calendar icon with a circle around a date, indicating a scheduled or highlighted day in a monthly view.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
